High-risk human papillomavirus (hrHPV) is an established carcinogen in the cervix, penis, vulva, vagina, anus and oropharynx. The discovery of virus-like particles (VLPs) that are both highly immunogenic and protective led to the licensure of several prophylactic VLP-based HPV vaccines for the prevention of cervical cancer. Vaccine-mediated, type-specific protection has been shown to be durable for at least a decade. Importantly, this protection was not absolutely type-specific because significant cross-protection. Vaccination did not eliminate the risk of cervical precancerous lesions or cervical cancer and are preventive not therapeutic. Therefore cervical screening is advised in vaccinated patients because of the potential for disease caused by hrHPVs other than those targeted by the licensed vaccines. Online Registration：Register |
